- All > Medicine Information and Evidence for Policy > Medicines Policy
- All > Medicine Access and Rational Use > Good Governance for Medicines
- All > Medicine Programme Coordination > Programme Coordination
- Keywords > access to medicines
- Keywords > accountability - pharmaceutical sector
- Keywords > availability, affordability, and quality of pharmaceutical products
- Keywords > corruption
- Keywords > key achievements
- Keywords > legal framework
- Keywords > MeTA - The Medicines Transparency Alliance
- Keywords > multi-stakeholder approach
- Keywords > pharmaceutical sector - good governance
- Keywords > transparency
(2015; 12 pages) [Russian]
There are many complex factors hindering access to medicines in Kyrgyzstan, but a common cause is weak systems. Monitoring medicines usage in hospitals has been near impossible because of a haphazard data entry system. Procurement law has mandated that medicines are bought on the basis of price without regard for quality. There has been little trust in the quality of medicines available in hospitals, so doctors have been known to advise patients to pay out of pocket for branded medicines. These can cost many times what they do in other countries, putting a heavy financial burden on the most vulnerable consumers. There has been a desperate need for medicines reform in Kyrgyzstan.
Kyrgyzstan launched a MeTA pilot in 2008. Through the programme, a small secretariat formed an 18-member MeTA Council, made up of representatives from civil society, the private sector, development partners and government, with the support of the WHO Country Office. The mission was to contribute to good governance, transparency and accountability across the medicines chain, through the engagement of all stakeholders with an interest in the outcome of the medicines market. Thanks to MeTA, academics and patients were sitting around the same table as professional associations, the private sector and government for the first time. They debated problems and identified solutions. Out of this process, transparency and new rigour has been brought to the policy-making dialogue. It has led to a reorientation of medicines policy in Kyrgyzstan to the needs of the patient, and has laid the foundations for a pathway to improved access to safe and effective, quality essential medicines and their rational use. As ownership of medicines policies and programmes is now shared by all stakeholders, there is optimism that reform will not only be implemented and enforced, but also sustainable and that there will be real change for the most vulnerable.
Kyrgyzstan is one of seven countries to adopt MeTA– the programme is also active in Ghana, Jordan, Peru, the Philippines, Uganda and Zambia. It is currently funded by the UK Government through the Department for International Development.